


Prostate Cancer Research Review™



Making Education Easy

Issue 78 - 2024

In this issue:

- > ¹⁷⁷Lu-PSMA-617 plus enzalutamide for mCRPC
- > AS uptake in men with low-risk prostate cancer
- > Birth weight and prostate cancer risk and mortality
- > Circulating tumour cell mRNA expression in different stages of prostate cancer
- > Annual mpMRI AS and PI-RADS upgrading
- > Missed prostate cancer diagnoses during COVID-19 pandemic
- > Clinical characterisation of prostate cancer receiving conservative management
- > Circulating GDF15/MIC-1 as a marker of response to docetaxel
- > Prostate gland evaluation with MRI after focal therapy
- > Impact of genomic biomarkers on a clinical risk prediction model

Abbreviations used in this issue:

ADT = androgen-deprivation therapy; AS = active surveillance;
AUC = area under the receiver operating characteristic curve;
CI = confidence interval; COVID-19 = coronavirus disease 2019;
IL = interleukin; Lu = lutetium;
mCRPC = metastatic castration-resistant prostate cancer;
mpMRI = multiparametric magnetic resonance imaging; OR = odds ratio;
OS = overall survival; PET = positron emission tomography;
PFS = progression-free survival; PSA = prostate-specific antigen;
PSMA = prostate-specific membrane antigen;
PI-RADS = Prostate Imaging-Reporting and Data System.

Follow us at:



SAVE
THE
DATE

[29.08.24 - 31.08.24]

MELBOURNE CONVENTION & EXHIBITION CENTRE
MELBOURNE, AUSTRALIA

Proudly sponsored by
Australian Prostate Cancer
apc



Welcome to Issue 78 of Prostate Cancer Research Review.

According to the findings of the phase II ENZA-p trial, the addition of [¹⁷⁷Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival in men with metastatic castration-resistant prostate cancer. In a large US study, we learn that while AS is the preferred management strategy for low-risk prostate cancer, not everyone takes it up. We conclude this issue with a study on the impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.

I hope you find the research in this issue useful to you in your practice and I look forward to your comments and feedback.

Kind Regards,

Professor Niall Corcoran

niall.corcoran@researchreview.com.au

[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): An open-label, multicentre, randomised, phase 2 trial

Authors: Emmett L et al.

Summary: This open-label, randomised, controlled phase II trial assessed the use of enzalutamide plus adaptive-dosed ¹⁷⁷Lu-PSMA-617 versus enzalutamide alone in 162 patients with mCRPC. After a median follow-up of 20 months, 32 (39%) enzalutamide plus ¹⁷⁷Lu-PSMA-617 and 16 (20%) enzalutamide alone recipients remained on treatment. Median PSA progression-free survival (PFS) was 13.0 months (95% CI 11.0-17.0) with enzalutamide plus ¹⁷⁷Lu-PSMA-617 and 7.8 months (95% CI 4.3-11.0) with enzalutamide alone (HR 0.43; 95% CI 0.29-0.63; p < 0.0001). The most common all grade adverse events were fatigue (75%), nausea (47%), and dry mouth (40%) in the enzalutamide plus ¹⁷⁷Lu-PSMA-617 group and fatigue (70%), nausea (27%), and constipation (23%) in the enzalutamide alone group; grade 3-5 adverse events occurred in 40% versus 41%. Grade 3 events occurring only in enzalutamide plus ¹⁷⁷Lu-PSMA-617 recipients included anaemia (4%) and decreased platelet count (1%).

Comment: Androgen receptor inhibition can increase PSMA expression in prostate cancer cells, suggesting potential synergy between agents directed against both targets. This is tested in this Australian open-label phase II study which randomised men with mCRPC to either enzalutamide alone or in combination with 2-4 doses (depending on persistence of PSMA-PET positive disease after 2 doses) of ¹⁷⁷Lu-PSMA-617 in the first-line setting. Eligible patients had PSMA-PET-positive disease with at least 2 risk factors for early progression with enzalutamide monotherapy. Combination treatment significantly improved PSA-PFS (the primary endpoint) with consistent positive effects across key secondary endpoints. However, given that more and more patients are being exposed to novel hormonal agents in the hormone sensitive phase of the disease it will be important to establish efficacy at this point.

Reference: *Lancet Oncol.* 2024;25(5):563-571

[Abstract](#)




Prostate Cancer Research Review™

Independent commentary by Professor Niall Corcoran.

Professor Niall Corcoran is a urological surgeon and translational scientist based in Melbourne. He is Head of the Urology Unit at Western Health and a visiting surgeon at Royal Melbourne and Frankston Hospitals. His group in the University of Melbourne Centre for Cancer Research investigates molecular drivers of prostate cancer metastases and treatment resistance.

RESEARCH REVIEW™ Australia's Leader in Specialist Publications



Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)

Authors: Xu J et al.

Summary: This US study examined determinants of uptake of active surveillance (AS) over definitive treatment among 1688 men with low-risk prostate cancer. Overall, 57% of patients chose AS (51% Black participants, 61% White), with unadjusted patient factors associated with initial AS uptake including older age, White race, and higher education. After adjustment for covariates, none of these factors predicted AS uptake. The strongest determinant was a recommendation by a urologist (adjusted prevalence ratio 6.59; 95% CI 4.84-8.97). Other factors included a shared patient-physician treatment decision, greater prostate cancer knowledge, and residence in metro-Detroit versus Georgia. Men who thought of their diagnosis as more serious were less likely to choose AS.

Comment: Although AS is the preferred management strategy for low-risk prostate cancer, not everyone takes it up, particularly in the US. This large cohort study explored factors associated with higher uptake in an ethnically diverse population. Almost 60% of men chose AS (with the remainder proceeding to definitive treatment), with by far the strongest influence being urologist treatment recommendation. This makes sense, as it is likely a surrogate for other clinical/pathological factors not measured in the study (number of cores involved, maximum linear length, MRI findings), which might influence the clinical recommendation. Of those factors that decrease adoption of AS, lack of understanding about risk of progression and over-estimating the 'curative' benefits of treatment were independently significant, suggesting better education and counselling could increase AS uptake even further.

Reference: *Cancer* 2024;130(10):1797-1806

[Abstract](#)

A prospective study of birth weight and prostate cancer risk and mortality in the Health Professionals Follow-up Study

Authors: Liu Q et al.

Summary: This analysis of data from the Health Professionals Follow-up Study assessed the association between self-reported birth weight and aggressive prostate cancer risk in 19,889 men. Overall, 2520 men were diagnosed with prostate cancer, with 643 having higher-grade/advanced stage disease, 296 with lethal disease, and 248 with fatal disease. There was no association between birth weight and overall prostate cancer, or lower-grade or organ-confined disease. There was a borderline trend for risk of higher-grade and/or advanced-stage prostate cancer with increasing birth weight (adjusted HR [aHR] per pound 1.05; 95% CI 0.99-1.11; $p = 0.08$); there were no associations with risk of lethal (aHR 0.99; 95% CI 0.91-1.08) or fatal (aHR 0.99; 95% CI 0.90-1.08) disease.

Comment: Higher birth weight is linked with an increased incidence of a range of different cancers, particularly breast cancer, by adversely impacting a number of different growth pathways during organ development. Similar biological mechanisms are hypothesised to be active during prostate organogenesis, with a number of small studies reporting an increase in the risk of both prostate cancer incidence as well as the development of clinically significant disease. This large and well-powered prospective cohort study nested within the larger Health Professionals Follow-up Study investigated the association between self-reported birth weight and subsequent development of prostate cancer over 22 years of follow-up. No significant association was observed between higher birth weight and any measure of future aggressive cancer, comprehensively putting this one to bed.

Reference: *Br J Cancer* 2024;130(8):1295-1303

[Abstract](#)

Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in different stages of prostate cancer

Authors: Cho H et al.

Summary: This prospective study examined whether a circulating tumour cell (CTC)-based transcript platform assessing mRNA expression of six transcripts (PSMA, PSA, AR, AR-V7, EpCAM, and KRT 19 mRNA) could identify potential prognostic markers in 21 healthy individuals and 247 prostate cancer patients (localised prostate cancer $n = 94$; metastatic hormone-sensitive prostate cancer [mHSPC] $n = 44$; mCRPC $n = 109$). CTC detection rates for localised prostate cancer, mHSPC, and mCRPC were 75.5%, 95.3%, and 98.0%. In localised prostate cancer, expression of PSMA (HR 3.35; $p = 0.028$) and PSA (HR 1.42; $p = 0.047$) mRNA were associated with biochemical recurrence. Patients with mHSPC with high PSMA (HR 4.26; $p = 0.020$) and PSA (HR 3.52; $p = 0.042$) mRNA expression had worse mCRPC-PFS rates than those with low PSMA and PSA expression. Increased PSA and PSMA expression was associated with shorter PSA-PFS and radiological PFS in patients with mCRPC, suggesting a possible drug resistance association.

Comment: CTC enumeration has been found to have prognostic relevance in advanced prostate cancer, however, CTCs are rarely detected in localised disease. In this context, this interesting Korean study reports CTC levels in various stages of prostate cancer, reporting positive detection in 73% of patients with localised disease, a third of whom had low-grade disease. It is likely that their highly sensitive method is detecting normal circulating prostate cells rather than tumour cells per se, as CTCs were also detected in healthy donors at a lower level, albeit not significantly different to patients with both localised prostate cancer and mHSPC. As such the observed interaction with PSA and PSMA expression probably reflects detection of 'true' CTC, suggesting a possible prognostic role in early disease with this assay.

Reference: *Clin Cancer Res.* 2024;30(9):1788-1800

[Abstract](#)

Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease

Authors: Greenberg JW et al.

Summary: This prospective, single-centre study assessed the utility of annual multiparametric mpMRI in 208 patients on AS, using radiologic upgrading and PI-RADS trends to identify clinically significant disease identified by subsequent biopsy. Men with a PI-RADS score of 3 and 5 at first mpMRI had similar biopsy Gleason grade reclassification-free survival to counterparts. However, men with an initial PI-RADS score of 4 had a shorter 5-year Gleason grade reclassification-free survival versus those with a PI-RADS score of 1-2. In a subset of 70 patients with ≥ 2 mpMRIs, those experiencing increasing mpMRI scores had a greater risk of Gleason grade reclassification, and a 35.4% difference in 5-year Gleason grade reclassification-free survival probability.


Comment: Traditional AS programs rely on regular interval prostate resampling to detect evidence of tumour progression even if other clinical parameters (PSA, clinical stage) remain stable. As evidence accumulates of the reliability of prostate MRI to detect evidence of progression, increasingly clinicians are opting to replace interval biopsies with interval MRIs. Further supporting this approach is this small prospective study from the US which found that men in whom the PI-RADS lesion score increased over time had a much greater risk of upgrading on subsequent biopsy than those in whom it decreased or remained stable. Good news for patients, and radiologists.

Reference: *Urol Oncol.* 2024;42(5):158.e11-158.e16

[Abstract](#)

Earn CPD

Nursing and Midwifery Board of Australia (NMBA) Journal reading and watching videos (including Research Reviews) may be considered a self-directed activity set out in the [NMBA Registration Standard: Continuing Professional Development](#). One hour of active learning will equal one hour of CPD. Details at [NMBA CPD page](#).



CONFIDENCE WITHOUT Compromise^{2-5*}



*Extend patients' lives without compromising quality of life

In mHSPC: NUBEQA® + ADT + docetaxel reduced the relative risk of death by 32.5% vs ADT + docetaxel (HR 0.68, 95% CI 0.57-0.80; P<0.001 [primary endpoint]); frequency of AEs and discontinuations were comparable to ADT + docetaxel alone.^{2,3}

In nmCRPC: NUBEQA® + ADT significantly improved OS vs ADT alone (HR 0.69, 95% CI 0.53-0.88; P=0.003 [secondary endpoint]); significantly improved MFS vs ADT alone (40.4 vs 18.4 months; HR 0.41, 95% CI 0.34-0.50; P<0.001 [primary endpoint]). Patient QOL was maintained throughout the duration of treatment; frequency of AEs and discontinuations were comparable to ADT alone.^{2,4,5}

NUBEQA® is indicated for the treatment of patients with mHSPC (in combination with docetaxel) and nmCRPC.²

ADT, androgen deprivation therapy; AE, adverse event; CI, confidence interval; HR, hazard ratio; MFS, metastasis-free survival; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, non-metastatic castration resistant prostate cancer; OS, overall survival; PBS, Pharmaceutical Benefits Scheme; QOL, quality of life.

NUBEQA®
(darolutamide) 300 mg tablets

PBS Information: This product is listed on the PBS for non-metastatic castration resistant prostate cancer and metastatic hormone-sensitive prostate cancer. Refer to PBS schedule for more information www.pbs.gov.au



Please review Product Information before prescribing. Full Product Information available upon request from Bayer Australia Ltd or by scanning the QR code.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.


MINIMUM PRODUCT INFORMATION NUBEQA® (darolutamide)

INDICATIONS: NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. **CONTRAINDICATIONS:** Hypersensitivity to darolutamide or excipients in tablet, women who are or may become pregnant. **PRECAUTIONS:** Cardiovascular events (the safety of darolutamide has not been characterised in patients with recent (within 6 months) cardiovascular events), hepatic impairment, renal impairment. The safety and efficacy in children and adolescents (< 18 years) have not been established. Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA. Patients should be monitored for signs and symptoms of ischemic heart disease. Optimise management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. Seizure occurred in patients receiving NUBEQA. Cases of idiosyncratic drug induced liver injury (DILI) consisting of Grade ≥ 3 increases in ALT and/or AST, including with concomitant bilirubin ≥2x ULN, have been reported with NUBEQA. In case of liver function test abnormalities suggestive of idiosyncratic DILI, permanently discontinue NUBEQA. **INTERACTIONS WITH OTHER MEDICINES:** Darolutamide is a substrate of CYP3A4, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Darolutamide is an inhibitor of BCRP and Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3 and a weak inducer of CYP3A4. In vitro data indicate darolutamide administration may inhibit OAT3, MATE1, MATE2K and intestinal MRP2. Darolutamide did not inhibit the transporters, BSEP, OAT1, OCTs, OATP2B1 and NTCP at clinically relevant concentrations. Please refer to the full Product Information for more information. **ADVERSE EFFECTS:** The most frequently observed adverse drug reaction (≥ 10%, very common) in patients with nmCRPC receiving NUBEQA is fatigue. The most frequently observed adverse drug reaction (>10%) in patients with mHSPC receiving NUBEQA in combination with docetaxel were constipation (23%), decreased appetite (19%), rash (19%) and hypertension (14%). Drug-induced liver injury with increases in ALT and AST has been reported in patients treated with NUBEQA in clinical trials. **Laboratory test abnormalities** include neutrophil count decrease, bilirubin increase and AST increase in nmCRPC patients. Laboratory test abnormalities include anaemia, white blood cell and neutrophil count decrease, ALT and AST increase, hyperglycaemia and hypocalcaemia in patients with mHSPC. Cases of idiosyncratic drug-induced liver injury with increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) to ≥5x and ≥20x upper limit of normal (ULN), including with concomitant bilirubin elevation ≥2x ULN, have been reported in patients treated with NUBEQA. Please refer to full Prescribing Information for a complete list of adverse effects and laboratory test abnormalities. **DOSAGE AND ADMINISTRATION:** 600 mg (two film-coated tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. The tablets should be taken whole with food. Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) analogue concurrently or should have had bilateral orchiectomy. In case of toxicity or an intolerable adverse reaction, dosing should be withheld or reduced. For more information see full Prescribing Information. **DATE OF PREPARATION:** August 2023, based on PI dated 23-August-2023.

References: 1. Pharmaceutical Benefits Scheme. www.pbs.gov.au. 2. NUBEQA® (darolutamide) Approved Product Information. 3. Smith MR et al. N Engl J Med 2022;386(12):1132-1142. 4. Fizazi K et al. N Engl J Med 2019;380(13):1235-1246 (including Supplementary Appendix). 5. Fizazi K et al. N Engl J Med 2020;383(11):1040-1049.

NUBEQA® is a registered trademark of Bayer Group, Germany, Bayer Australia Limited. ABN 22 000 138 714. 875 Pacific Highway, Pymble NSW 2073. NUB194 | January 2024 | PP-NUB-AU-0273-2





During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England

Authors: Lemanska A et al.

Summary: This analysis of the English OpenSAFELY-TPP dataset (n =24 million) assessed the effect of the COVID-19 pandemic on prostate cancer incidence, prevalence, and mortality from January 2015 to July 2023. Recorded incidence declined by 4772 (31%) cases in 2020 (15,550 vs 20,322; 95% CI 19,241-21,403) and by 3148 cases in 2021 (18%; 17,950 vs 21,098; 95% CI 19,740-22,456). In 2022, incidence had returned to expected levels. Age at diagnosis shifted towards older men, from 71.6 years (95% CI 71.5-71.8) in 2020 and 71.8 years (95% CI 71.7-72.0) in 2021 versus 71.3 years (95% CI 71.1-71.4) in 2019.

Comment: It was predicted that the reduction in routine cancer screening during the COVID-19 pandemic would lead to a delay in diagnosis and a subsequent increase in late presentation; however, only now is the potential scale of the problem becoming evident. This prospective cohort study used NHS-England data to estimate the number of prostate cancer cases missed, reporting a greater than 30% reduction in diagnoses compared to preceding years. This equates to more than 20,000 missed diagnoses of prostate cancer, who based on current figures are still yet to enter the healthcare system. How this will impact patient outcomes is unclear, but if even a fraction of the patients progress to requiring long-term systemic therapy it will likely prove costly from a healthcare payers' perspective.

Reference: *BJU Int.* 2024;133(5):587-595

[Abstract](#)

Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: A PIONEER analysis based on big data

Authors: Gandaglia G et al.

Summary: The PIONEER analysis used data from 8 databases to describe clinical characteristics and long-term outcomes of 12,146 newly diagnosed prostate cancer patients receiving conservative management (did not receive curative or palliative treatment for ≥6 months after diagnosis). The most common comorbidities in these patients were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of prostate cancer-related symptomatic progression ranged from 2.6% to 6.2%. During the 1st year of follow-up, hospitalisation (12-25%) and emergency department visits (10-14%) were common, while the probability of being free from both palliative and curative treatments decreased during follow-up.

Comment: PIONEER, part of the European Innovative Medicine Initiative's (IMI's) "Big Data for Better Outcomes" program aims to improve care through the application of big data analysis. This initial report looked at data from 8 European and US electronic health-related registries (medical records, claims data) to identify men treated with observation for at least the first 6 months following diagnosis. They report common co-morbidities within the cohort as well as rates of symptomatic progression and intervention with curative or palliative intent. However, key data are missing, such as clinical and pathological characteristics as well as more importantly the 'intent' of observation (AS vs watchful waiting), which makes it very difficult to discern any meaningful insights from the data.

Reference: *Eur Urol.* 2024;85(5):457-465

[Abstract](#)

Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer

Authors: Mahon KL et al.

Summary: This study assessed level 2 evidence of cytokine biomarker utility associated with resistance to docetaxel in patients with mCRPC. In 120 patients, higher growth differentiation factor (GDF15/MIC-1) levels at baseline (p = 0.03) and day 21 (p = 0.004) of docetaxel treatment were associated with shorter OS, but IL-4 and IL-6 levels were not associated with outcomes. In another cohort of 430 patients, higher GDF15 levels at baseline (p < 0.0001) and day 42 (p < 0.0001) predicted shorter OS. Plasma samples from men with high GDF15 levels caused an increase in monocyte CD86 expression (p = 0.03), but this effect was not observed with recombinant GDF15.

Comment: Previous work has identified that an anti-inflammatory response mediated by tumour associated macrophages contributes to docetaxel resistance in CRPC. This study from Kate Mahon in Sydney investigated the association between specific cytokines measured at baseline and end of cycle 1 or 2 with OS in men with mCRPC treated with docetaxel. Only elevated levels of GDF15, previously known as macrophage inhibitory cytokine-1, were associated with a shorter OS independent of other established prognostic markers. Interestingly, plasma from patients with high GDF15 was shown to activate monocytes *in vitro*, whereas recombinant GDF15 did not, suggesting GDF15 is a marker rather than a mediator of the response.

Reference: *Prostate* 2024;84(8):747-755

[Abstract](#)

Earn CPD

Royal Australasian College of Physicians (RACP) MyCPD participants can claim the time spent reading and evaluating research reviews as CPD in the online [MyCPD program](#). Please contact MyCPD@racp.edu.au for any assistance.


Royal Australian & New Zealand College of Radiologists (RANZCR) members can claim reading related to their practice as a CPD activity under the category 'journal reading and web based no certificate *reflection required'. [More info.](#)

Kindly Supported by



RESEARCH REVIEW™

Australia's Leader in Specialist Publications



The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A systematic review and international consensus recommendations

Authors: Light A et al.

Summary: This systematic review aimed to develop consensus statements on MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer based on 73 studies. In 20 studies reporting suspicious imaging features, all cited focal contrast enhancement as suspicious for cancer recurrence, while among 31 studies reporting MRI assessment criteria, the PI-RADS score was used most often (20 studies; 65%), followed by 5-point Likert scores (6 studies; 19%). Key recommendations include performing routine MRI at 12 months using an mpMRI compliant with PI-RADS version 2.1 standards. PI-RADS scores for assessing recurrence within ablation zones should be avoided. An alternative 5-point scoring system using a major dynamic contrast enhancement (DCE) sequence and minor diffusion-weighted and T2-weighted sequences was proposed. In the DCE sequence, focal nodular strong early enhancement was considered the most suspicious finding.

Comment: How do you know if focal therapy has worked? This international group performed a systematic literature review of the role of MRI in detecting recurrent disease after focal ablation to develop some management guidelines. The main recommendations were to perform annual MRIs for surveillance, regardless of negative finding on interval biopsy (if done), and to use DCE sequences as the dominant sequence to detect recurrence in the ablation zone findings reported on a 5-point Likert scale rather than using the PI-RADS system. For lesions outside the ablation zone, both the PI-RADS and the 5-point score should be reported. Good to get some practical recommendations, but I'm still not sure how to tell if focal therapy has worked; as it turns out, neither do the people who do it.

Reference: *Eur Urol.* 2024;85(5):466-482

[Abstract](#)

The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer

Authors: Braun AE et al.

Summary: This study sought to assess the impact of genomic classifiers on upgrading or upstaging risk prediction in a clinicopathologic model to distinguishing indolent from aggressive prostate cancer using data from 864 men for the prediction model (cohort 1) and validated in 2267 participants (cohort 2). The prediction model included biopsy Gleason grade group 1 versus Gleason grade group 2 (OR 5.83; 95% CI 3.73-9.10), PSA (OR 1.10; 95% CI 1.01-1.20; per 1 ng/mL), percent positive biopsy cores (OR 1.01 per 1%; 95% CI 1.01-1.02), prostate volume (OR 0.98 per mL; 95% CI 0.97-0.99), and age (OR 1.05 per year; 95% CI 1.02-1.07), and had an AUC of 0.70 (cohort 1) and AUC of 0.69 (cohort 2). Oncotype Dx Genomic Prostate Score was associated with upgrading or upstaging (OR 1.03; 95% CI 1.01-1.06; $p < 0.01$) and an AUC of 0.72, indicating a similar performance to the prediction model.

Comment: Clinical outcomes for men with favourable intermediate-risk disease are quite heterogenous. The vast majority follow an indolent course; however, a small group of men have more aggressive disease with the potential to metastasise in the absence of, or despite, early radical treatment. This prospective cohort study measured the utility of two transcription-based tumour assays (Oncotype Dx or Prolaris) measured in diagnostic biopsies to improve on a clinical risk predictor of subsequent tumour upgrading and/or upstaging (in those who underwent surgery) in men with low-risk or low-volume favourable intermediate-risk prostate cancer undergoing prostatectomy. Overall, the transcriptional assays added little to the clinical model in terms of predicting more adverse pathology, an inaccurate surrogate endpoint of disease 'lethality'. The appropriate measure should have been development of metastases in patients treated conservatively.

Reference: *Cancer* 2024;130(10):1766-1772

[Abstract](#)

Research Review has you covered 50+ clinical areas

Update your subscription at
www.researchreview.com.au

Login to your profile and update your subscriptions. Trouble logging in – Email Us



RESEARCH REVIEW

Australia's Leader in Specialist Publications

Australian Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Research Reviews are prepared with an independent commentary from relevant specialists. To become a reviewer please email geoff@researchreview.com.au.

Research Review Australia Pty Ltd is an independent Australian publisher. Research Review receives funding from a variety of sources including Government depts., health product companies, insurers and other organisations with an interest in health. Journal content is created independently of sponsor companies with assistance from leading local specialists. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for Australian health professionals.

